Abstract
BackgroundPancreatic cancer patients remain largely unresponsive to single agent immune checkpoint blockade (ICB) therapy. This refractory state originates from PDAC’s unique immunosuppressive microenvironment that is densely populated by suppressive myeloid...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have